Misplaced Pages

Alogliptin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by The chemistds (talk | contribs) at 23:23, 10 October 2011 (added CSID, (Std)InChI & (Std)InChIKey). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 23:23, 10 October 2011 by The chemistds (talk | contribs) (added CSID, (Std)InChI & (Std)InChIKey)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Alogliptin
Clinical data
Routes of
administration		Oral
ATC code
Identifiers
IUPAC name
  • 2-({6--3-methyl-2,4-dioxo-
    3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.256.501 Edit this at Wikidata
Chemical and physical data
FormulaC18H21N5O2
Molar mass339.39 g/mol g·mol
3D model (JSmol)
SMILES
  • N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC(N)C2
InChI
  • InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
  • Key:ZSBOMTDTBDDKMP-OAHLLOKOSA-N
  (verify)

Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class, being developed by Takeda Pharmaceutical Company. In January 2008, Takeda submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials. However, the FDA submission was suspended or withdrawn in June 2009 needing more data.

References

  1. Feng J, Zhang Z, Wallace MB; et al. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–300. doi:10.1021/jm070104l. PMID 17441705. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  2. "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4, 2008. Retrieved 2008-01-09.
  3. "GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy". Genetic Engineering and Biotechnology News. 4 June 2009.
Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)
Insulins / insulin analogs
fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
  • Exubera
  • Afrezza
Non-insulins
Insulin sensitizers
Biguanides
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Amylin analogs and DACRAs
Secretagogues
KATP
Sulfonylureas
Meglitinides/"glinides"
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors/"gliptins"
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors/"gliflozins"
Other
Combinations


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: